IRIS
BERGAMASCHI, MICAELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.693
AS - Asia 9
SA - Sud America 3
NA - Nord America 1
Totale 1.706
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 1.693
CN - Cina 6
BR - Brasile 2
SG - Singapore 2
PY - Paraguay 1
US - Stati Uniti d'America 1
VN - Vietnam 1
Totale 1.706
Salva come PNG Salva come JPEG
Città #
Genova 879
Genoa 502
Rapallo 180
Vado Ligure 130
Bordighera 2
Ashburn 1
Beijing 1
Chapada Gaúcha 1
Ciudad del Este 1
Hanoi 1
Maceió 1
Totale 1.699
Salva come PNG Salva come JPEG
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 221
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 212
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 147
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 135
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 131
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 127
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 122
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 121
Un cas de cryptococcose cutanèe primitive sans diffusion systemique chez un patient immunodeprimé 108
Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. 102
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 79
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 78
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 74
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 62
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 61
Totale 1.780
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.896
article - articoli 6.531
book - libri 0
conference - conferenze 365
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.792
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 21 14 34 22 14 33 14 7
2021/2022179 8 2 5 22 3 14 3 38 18 12 12 42
2022/2023217 21 25 3 24 35 36 0 18 31 3 20 1
2023/2024115 10 10 3 19 10 22 5 14 3 1 2 16
2024/2025361 12 18 8 26 35 43 33 91 7 18 33 37
2025/2026143 75 15 27 26 0 0 0 0 0 0 0 0
Totale 1.780